Immunome, Inc. short interest in 2024
In 2024, Immunome, Inc.'s disclosed short interest ran from 5.43% of shares outstanding on 28 Mar 2024 to 15.82% on 31 Dec 2024, a change of +10.39 percentage points. The year's high was 23.08% on 31 Jul 2024 and its low 5.43% on 28 Mar 2024, averaging 16.18% across 19 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 33.47 days on 30 Aug 2024. Full history: Immunome, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2024 in figures
- Start of year
- 5.43% (28 Mar 2024)
- End of year
- 15.82% (31 Dec 2024)
- Change
- +10.39 pp
- High
- 23.08% (31 Jul 2024)
- Low
- 5.43% (28 Mar 2024)
- Average
- 16.18%
- Highest days to cover
- 33.47 (30 Aug 2024)
- SEC filings marked
- 9
Every report in 2024
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 28 Mar 2024 | 5.43% | 5.75 | results (8-K), 10-K filed, results (8-K) |
| 15 Apr 2024 | 6.28% | 6.04 | |
| 30 Apr 2024 | 9.18% | 5.29 | |
| 15 May 2024 | 10.26% | 8.59 | 10-Q filed, results (8-K) |
| 31 May 2024 | 13.52% | 8.86 | |
| 14 Jun 2024 | 14.90% | 12.80 | |
| 28 Jun 2024 | 18.82% | 5.03 | |
| 15 Jul 2024 | 22.55% | 22.69 | |
| 31 Jul 2024 | 23.08% | 22.08 | |
| 15 Aug 2024 | 20.89% | 19.56 | 10-Q filed, results (8-K) |
| 30 Aug 2024 | 22.12% | 33.47 | |
| 13 Sep 2024 | 20.72% | 26.49 | |
| 30 Sep 2024 | 21.44% | 12.29 | |
| 15 Oct 2024 | 18.19% | 17.16 | |
| 31 Oct 2024 | 17.43% | 22.27 | |
| 15 Nov 2024 | 17.09% | 12.42 | 10-Q filed, results (8-K) |
| 29 Nov 2024 | 15.68% | 8.70 | |
| 13 Dec 2024 | 14.10% | 12.77 | |
| 31 Dec 2024 | 15.82% | 9.82 |
See also: Immunome, Inc.'s full history · most shorted US stocks of 2024 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.